IMPACT OF PHOTOBIOMODULATION THERAPY IN A PATIENT-DERIVED XENOGRAFT MODEL OF ORAL SQUAMOUS CELL CARCINOMA

Abstract

Objectives This study aimed to evaluate the effect of photobiomodulation therapy (PBMT) in an oral squamous cell carcinoma (OSCC) patient-derived xenograft (PDX) model. Study Design BALB/c nude mice with OSCC-PDX models were divided into nonirradiated and irradiated groups. OSCC-PDX were irradiated daily (660 nm; 100 mW; 6 J/cm2; 0.2 J/point) for 12 weeks. The tumors were collected and submitted to volumetric, histologic, immunohistochemical, and cell cycle analysis. Results No significant differences in the volumetric measurements (P = .89) and in the histopathologic grade (P > .05) were detected between the groups. The immunohistochemical analysis of Ki-67 (P = .9661), H3K9ac (P = .3794), and BMI1 (P = .5182) and the evaluation of the cell cycle phases (P > .05) by flow cytometry also did not demonstrate significant differences between the irradiated and nonirradiated groups. Conclusions In this study, PBMT did not affect the behavior of OSCC-PDX models. This is an important preclinical outcome regarding safety concerns of the use of PBMT in patients with cancer. This study aimed to evaluate the effect of photobiomodulation therapy (PBMT) in an oral squamous cell carcinoma (OSCC) patient-derived xenograft (PDX) model. BALB/c nude mice with OSCC-PDX models were divided into nonirradiated and irradiated groups. OSCC-PDX were irradiated daily (660 nm; 100 mW; 6 J/cm2; 0.2 J/point) for 12 weeks. The tumors were collected and submitted to volumetric, histologic, immunohistochemical, and cell cycle analysis. No significant differences in the volumetric measurements (P = .89) and in the histopathologic grade (P > .05) were detected between the groups. The immunohistochemical analysis of Ki-67 (P = .9661), H3K9ac (P = .3794), and BMI1 (P = .5182) and the evaluation of the cell cycle phases (P > .05) by flow cytometry also did not demonstrate significant differences between the irradiated and nonirradiated groups. In this study, PBMT did not affect the behavior of OSCC-PDX models. This is an important preclinical outcome regarding safety concerns of the use of PBMT in patients with cancer.